Literature DB >> 6754076

Autologous bone marrow transplantation in acute myeloid leukemia in relapse or in complete remission.

P Herve, A Rozenbaum, E Plouvier, M Flesch, J Y Cahn, A Farradji, J P Bergerat, J C Adjizian, B Pignon.   

Abstract

We report ten cases of acute myeloid leukemia treated by intensive therapy followed by autologous bone marrow transplantation. Seven patients were in first relapse, and three were in complete remission. The conditioning regimen consisted of either chemotherapy alone (6-thioguanine, cytarabine, lomustine, and cyclophosphamide [TACC; eight patients]) or cyclophosphamide and total-body irradiation (two patients). All the patients in first relapse achieved complete remission (CR). The median remission duration was 9.9 months (range, 5-14), and the median survival was 14.4 months (range, 9-23.8). Of the three patients autografted during CR, one relapsed at Month 5 and two others remain in CR and are well at 18+ and 18.3+ months. High-dose chemotherapy followed by autologous bone marrow transplantation seems to be a valuable treatment for acute myeloid leukemia, if it is used immediately after the CR to consolidate the remission.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6754076

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  2 in total

1.  Autologous bone marrow transplantation for acute leukemia using transplant chemopurified with metabolite of oxazaphosphorines (ASTA Z 7557, INN mafosfamide). First clinical results.

Authors:  P Hervé; J Y Cahn; E Plouvier; M Flesch; E Tamayo; R Leconte des Floris; A Peters
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

2.  Pharmacokinetic and metabolic studies of high-dose busulphan in adults.

Authors:  M Hassan; G Oberg; H Ehrsson; M Ehrnebo; I Wallin; B Smedmyr; T Tötterman; S Eksborg; B Simonsson
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.